Spoerl Steffen, Gerken Michael, Fischer René, Spoerl Silvia, Kirschneck Christian, Wolf Stefanie, Taxis Juergen, Ludwig Nils, Biermann Niklas, Reichert Torsten E, Spanier Gerrit
Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, 93042 Regensburg, Germany.
Tumor Center, Institute for Quality Management and Health Services Research, University of Regensburg, 93053 Regensburg, Germany.
Biomedicines. 2023 Jan 27;11(2):369. doi: 10.3390/biomedicines11020369.
The anti-cancer properties of statins have attracted much attention recently, but little is known about the prognostic role of statins in oral squamous cell carcinoma (OSCC). In a retrospective approach, we analyzed a population-based cohort of 602 OSCC patients with primary curative tumor resection to negative margins and concomitant neck dissection between 2005-2017. Long-term medication with statins was correlated with overall survival (OAS) as well as recurrence-free survival (RFS) using uni- and multivariable Cox regression. Additionally, propensity score matching was applied to adjust for confounders. Statin use was present in 96 patients (15.9%) at a median age of 65.7 years. Statin treatment correlated with ameliorated survival in multivariable Cox regression in the complete cohort (OAS: HR 0.664; 95% CI 0.467-0.945, = 0.023; RFS: HR 0.662; 95% CI 0.476-0.920, = 0.014) as well as matched-pair cohort of OSCC patients (OAS: HR 0.691; 95% CI 0.479-0.997, = 0.048; RFS: HR 0.694; 95% CI 0.493-0.976, = 0.036) when compared to patients not taking statins at time of diagnosis. These findings were even more pronounced by sub-group analysis in the matched-pair cohort (age < 70 years). These data indicate that statin use might ameliorate the oncological outcome in primarily resected OSCC patients, but prospective clinical trials are highly recommended.
他汀类药物的抗癌特性最近备受关注，但关于他汀类药物在口腔鳞状细胞癌（OSCC）中的预后作用却知之甚少。我们采用回顾性研究方法，分析了2005年至2017年间602例接受原发性根治性肿瘤切除且切缘阴性并同期进行颈部清扫的OSCC患者的人群队列。使用单变量和多变量Cox回归分析，长期服用他汀类药物与总生存期（OAS）以及无复发生存期（RFS）相关。此外，应用倾向评分匹配法来调整混杂因素。96例患者（15.9%）使用了他汀类药物，中位年龄为65.7岁。在整个队列的多变量Cox回归分析中，他汀类药物治疗与改善生存相关（OAS：风险比[HR] 0.664；95%置信区间[CI] 0.467 - 0.945，P = 0.023；RFS：HR 0.662；95% CI 0.476 - 0.920，P = 0.014），在OSCC患者的匹配对列中也是如此（OAS：HR 0.691；95% CI 0.479 - 0.997，P = 0.048；RFS：HR 0.694；95% CI 0.493 - 0.976，P = 0.036），与诊断时未服用他汀类药物的患者相比。在匹配对列的亚组分析（年龄<70岁）中，这些发现更加明显。这些数据表明，使用他汀类药物可能改善原发性切除的OSCC患者的肿瘤学结局，但强烈建议进行前瞻性临床试验。
